Mermaid Medical Group® Achieves Zero Non-Conformities in ISO 14001 Environmental Audit
Mermaid Medical Group® is proud to share that it has successfully passed its ISO 14001 audit with zero non-conformities identified.
Mermaid Medical® Group is excited to announce that our partner, Danderyd Hospital in Sweden, is now offering microwave ablation (MWA) as a treatment for uterine fibroids, following the success of several clinical studies.
These studies[1] highlight the potential advantages of MWA over traditional approaches such as Uterine Artery Embolization (UAE). While both are minimally invasive treatments aimed at reducing fibroid volume and relieving symptoms, MWA has demonstrated shorter hospital stays and faster recovery times, which can help improve patient comfort and reduce healthcare costs.
How MWA Works
MWA uses microwave energy to heat and destroy fibroid tissue, which results in fibroid shrinkage and symptom relief. In contrast, UAE works by injecting tiny particles into the uterine arteries to block blood flow to the fibroids, causing them to shrink over time.
MaxBlate® MWA System
At Danderyd Hospital, the procedure is performed using the MaxBlate® Microwave Ablation System. Designed for precision, control, and consistency, MaxBlate® enables safe and effective treatment of both benign and malignant tumors in organs such as the liver, kidneys, lungs, thyroid - and now, the uterus. MaxBlate® provides clinicians with a high-performance solution for fibroid ablation.
Shared Vision
At Mermaid Medical Group, we’ve worked closely with the skilled team at Danderyd Hospital to bring this treatment option to patients. Entering the gynecological treatment landscape has long been part of our vision, and we’re excited to see it become a reality. We look forward to continuing our work in this area and helping bring better care to people living with uterine conditions.
[1] Microwave ablation as treatment of benign uterine disease
Mermaid Medical Group® is proud to share that it has successfully passed its ISO 14001 audit with zero non-conformities identified.
Mermaid Medical Group® is pleased to announce an exclusive distribution agreement with MicroPort® for two cardiovascular devices: the VitaFlow Liberty™ Aortic Valve & Delivery System and Anchorman™ for LAAC procedures.
Mermaid Medical Group is excited to introduce its latest product addition: the Full Core Biopsy Device - designed with both optimal biopsy sample quality and user ergonomics in mind.